home / stock / ubx / ubx news


UBX News and Press, Unity Biotechnology Inc.

Stock Information

Company Name: Unity Biotechnology Inc.
Stock Symbol: UBX
Market: NASDAQ
Website: unitybiotechnology.com

Menu

UBX UBX Quote UBX Short UBX News UBX Articles UBX Message Board
Get UBX Alerts

News, Short Squeeze, Breakout and More Instantly...

UBX - Expected US Company Earnings on Tuesday, August 5th, 2025

SOPHiA GENETICS SA (SOPH) is expected to report for Q2 2025 Investors Title Company (ITIC) is expected to report for Q2 2025 Safehold Inc. (SAFE) is expected to report $0.39 for Q2 2025 First Guaranty Bancshares Inc. (FGBI) is expected to report $-0.2 for Q2 2025 United Fire Group...

UBX - Expected earnings - Unity Biotechnology Inc.

Unity Biotechnology Inc. (UBX) is expected to report $-0.3 for Q2 2025

UBX - EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

2025-06-12 11:03:51 ET Investment Overview Back in January this year, I covered EyePoint Pharmaceuticals, Inc. ( EYPT ) in a note for Seeking Alpha , calling its stock a "risky buy" ahead of a key readout for its lead and only clinical stage drug candidate Du...

UBX - Expected US Company Earnings on Tuesday, May 13th, 2025

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

UBX - UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST <400 microns (60...

UBX - UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Pha...

UBX - UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published...

UBX - Unity Biotechnology GAAP EPS of -$0.43 misses by $0.03

2025-04-22 16:50:32 ET More on Unity Biotechnology UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial infor...

UBX - UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY annou...

UBX - UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial

2025-03-24 09:29:48 ET More on Unity Biotechnology Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology Read the full article on Seeking Alpha For fur...

Next 10